EPO and Cognitive impairment: In ELGAN study subjects, endogenous EPO concentrations at 2 weeks of life, regardless of intermittent or sustained systemic inflammation, were associated with low mental and/or psychomotor development indices and microcephaly at 2 years [9] and with cognitive impairment at 10 years [10].